Airspace Disease: Symptoms, Diagnosis & Treatment

Airspace disease, characterized by abnormalities in the lung parenchyma, presents a significant challenge in respiratory medicine, requiring precise diagnostic approaches and tailored treatment strategies. The American Thoracic Society (ATS), a leading authority in pulmonary health, provides guidelines for the evaluation of these conditions, emphasizing the importance of high-resolution computed tomography (HRCT) in identifying specific patterns of involvement. Manifestations can range from subtle infiltrates to extensive consolidation, often necessitating differentiation from conditions like pulmonary edema or pneumonia, managed with tools such as arterial blood gas (ABG) analysis to assess the severity of respiratory compromise. Early and accurate diagnosis, ideally guided by the expertise of a pulmonologist like Dr. Albert G. Rider, is crucial to mitigate potential complications and improve patient outcomes in individuals affected by airspace disease.

Image taken from the YouTube channel Radiology Education by Joseph W. Owen, MD , from the video titled Chest Radiology - Patterns - Airspace .

Decoding Airspace Disease: A Critical Overview

Airspace disease represents a spectrum of pulmonary conditions that fundamentally disrupt the lung's architecture and, consequently, its capacity for effective respiration. These diseases, impacting the alveoli and small airways—the very sites of gas exchange—can manifest in diverse ways, posing significant diagnostic and therapeutic challenges. A clear understanding of these conditions is paramount for healthcare professionals to ensure accurate diagnoses and timely, effective interventions.

The Impact on Respiratory Function

The primary function of the lungs is to facilitate the exchange of oxygen and carbon dioxide between the air and the bloodstream. Airspace diseases directly compromise this function. Any process that fills, collapses, or inflames the airspaces hinders the diffusion of gases, leading to hypoxemia (low blood oxygen) and hypercapnia (elevated blood carbon dioxide). This impairment can manifest as shortness of breath, reduced exercise tolerance, and, in severe cases, respiratory failure.

The mechanical properties of the lung can also be affected. For instance, consolidation (the filling of airspaces with fluid or cells) reduces lung compliance, making it harder to inflate the lungs. This increased work of breathing can exacerbate respiratory distress.

Defining Airspace Disease

Airspace disease encompasses a range of abnormalities primarily affecting the alveoli and small airways, the terminal portions of the respiratory tract. These abnormalities typically involve:

• Filling of the airspaces: This can occur with fluid (as in pulmonary edema), inflammatory cells (as in pneumonia), blood (as in pulmonary hemorrhage), or proteinaceous material (as in alveolar proteinosis).

• Collapse of the airspaces: Atelectasis, or lung collapse, reduces the available surface area for gas exchange, leading to ventilation-perfusion mismatch and hypoxemia.

  You also like

  How to Make Ice Chips: 5 Easy Methods & Expert Tips

• Inflammation of the airspaces: Pneumonitis, an inflammatory process affecting the lung parenchyma, can cause edema, cellular infiltration, and impaired gas exchange.

Airspace diseases are often contrasted with interstitial lung diseases, which primarily affect the supporting tissues of the lung rather than the airspaces themselves. However, considerable overlap can exist, and some conditions may involve both compartments.

Significance of Understanding and Management

A comprehensive understanding of airspace disease is critical due to several factors:

• Diverse Etiologies: Airspace diseases can arise from a multitude of causes, including infections, cardiac conditions, inflammatory processes, and environmental exposures. Accurate diagnosis requires careful consideration of the patient's clinical history, risk factors, and imaging findings.

• Variable Clinical Presentations: The clinical manifestations of airspace disease can vary widely, ranging from mild symptoms to life-threatening respiratory failure. Recognizing the subtle signs and symptoms is essential for early detection and intervention.

• Impact on Patient Outcomes: Untreated or poorly managed airspace disease can lead to significant morbidity and mortality. Effective management requires a multidisciplinary approach, including appropriate medical therapies, supportive care, and, in some cases, invasive procedures.

The ability to differentiate between various airspace diseases and implement appropriate treatment strategies is paramount. This article will delve into the causes, diagnostic approaches, and management strategies for these complex pulmonary conditions, aiming to equip healthcare professionals with the knowledge needed to improve patient outcomes.

Unveiling the Causes: Etiology and Pathophysiology

Understanding airspace disease requires a comprehensive grasp of its diverse etiologies and the underlying pathophysiological mechanisms that disrupt normal lung function. From infectious agents to hydrostatic imbalances, a variety of insults can trigger abnormalities within the alveolar spaces. Delving into these causes is crucial for accurate diagnosis and targeted treatment strategies.

Infectious Causes: Pneumonia

Pneumonia, an infection of the lung parenchyma, is a significant cause of airspace disease. It is broadly categorized by the causative agent: bacterial, viral, or fungal.

Bacterial pneumonia is often characterized by alveolar consolidation, resulting from an influx of inflammatory cells and fluid into the airspaces. Common pathogens include Streptococcus pneumoniae, Haemophilus influenzae, and Klebsiella pneumoniae.

Viral pneumonia typically presents with a more diffuse pattern of inflammation, affecting both the alveolar spaces and the interstitial tissue. Viruses such as influenza, respiratory syncytial virus (RSV), and adenovirus are frequent culprits.

Fungal pneumonia, while less common, can occur in immunocompromised individuals or those exposed to specific environmental fungi such as Pneumocystis jirovecii or Aspergillus.

Pulmonary Edema: Cardiogenic and Non-Cardiogenic

Pulmonary edema, the abnormal accumulation of fluid in the lungs, represents another major category of airspace disease. It is generally divided into cardiogenic and non-cardiogenic forms.

Cardiogenic pulmonary edema arises from elevated hydrostatic pressure in the pulmonary capillaries, usually secondary to left ventricular failure. This increased pressure forces fluid into the alveolar spaces, impairing gas exchange.

Non-cardiogenic pulmonary edema, also known as acute respiratory distress syndrome (ARDS), results from increased permeability of the alveolar-capillary barrier. This permeability is often triggered by inflammatory mediators released in response to systemic illnesses, direct lung injury, or sepsis.

Inflammatory Conditions: Aspiration Pneumonitis and ARDS

Inflammatory conditions, such as aspiration pneumonitis and acute respiratory distress syndrome (ARDS), can lead to significant airspace abnormalities.

Aspiration pneumonitis occurs when gastric contents are inhaled into the lungs, causing an acute inflammatory reaction. The acidic gastric fluid can directly damage the alveolar epithelium, leading to edema and impaired gas exchange.

Acute Respiratory Distress Syndrome (ARDS) represents a severe form of acute lung injury characterized by diffuse alveolar damage and increased permeability of the alveolar-capillary barrier. ARDS can be triggered by a wide range of insults, including sepsis, pneumonia, trauma, and pancreatitis. The resulting inflammation leads to pulmonary edema, hypoxemia, and respiratory failure.

Other Specific Diseases

Beyond the more common causes, several other specific diseases can manifest as airspace disease.

Alveolar proteinosis is a rare disorder characterized by the accumulation of surfactant-derived lipoproteinaceous material within the alveolar spaces. This accumulation impairs gas exchange and can lead to progressive respiratory dysfunction.

Pulmonary hemorrhage involves bleeding into the alveolar spaces. It can result from various causes, including vasculitis, trauma, coagulopathies, and certain infections. The presence of blood within the alveoli can disrupt gas exchange and cause respiratory distress.

Understanding the varied etiologies and pathophysiological mechanisms underlying airspace disease is paramount for guiding appropriate diagnostic and therapeutic interventions, ultimately improving patient outcomes.

Diagnostic Toolkit: Identifying Airspace Disease

After identifying the potential causes, a crucial step in managing airspace disease is accurate identification. A range of diagnostic modalities are available, each playing a vital role in pinpointing the underlying pathology. From initial clinical assessments to advanced imaging and invasive procedures, a comprehensive approach is essential for reaching a definitive diagnosis. Each method offers unique insights, and their judicious application is key to tailoring appropriate treatment strategies.

The Foundation: Initial Assessment

The diagnostic process often begins with a thorough initial assessment, typically conducted by a primary care physician or an emergency medicine physician. This initial step relies heavily on a detailed medical history and a careful physical examination.

The medical history should encompass:

• Onset and duration of symptoms
• History of respiratory illnesses
• Exposure to environmental or occupational hazards
• Smoking history
• Medication review

The physical examination includes:

• Auscultation of the lungs
• Assessment of breathing patterns
• Evaluation for signs of respiratory distress, such as:
  • Accessory muscle use
  • Cyanosis

This primary assessment sets the stage for further investigations.

Radiological Evaluation: Seeing is Believing

Chest X-ray: A First Glance

Chest radiography (X-ray) is frequently the first-line imaging modality used in evaluating airspace disease. It offers a broad overview of the lungs and can reveal:

• Areas of consolidation
• Fluid accumulation
• Other gross abnormalities.

While valuable as an initial screening tool, chest X-rays may have limitations in detecting subtle or early-stage changes.

Computed Tomography (CT) Scan: Enhanced Visualization

Computed Tomography (CT) scans provide more detailed images of the lung parenchyma than traditional X-rays. High-Resolution CT (HRCT) is particularly useful for:

• Evaluating interstitial lung diseases
• Detecting subtle changes in lung architecture
• Visualizing the extent and distribution of airspace abnormalities

CT scans offer invaluable information for differentiating between various causes of airspace disease and guiding further diagnostic or therapeutic interventions.

Invasive Procedures: Direct Tissue Examination

In cases where non-invasive methods are inconclusive, invasive procedures may be necessary to obtain tissue samples for analysis.

Bronchoscopy: Visualizing the Airways

Bronchoscopy involves inserting a flexible tube with a camera into the airways to visualize the trachea, bronchi, and bronchioles.

During bronchoscopy, clinicians can:

• Collect bronchoalveolar lavage (BAL) fluid
• Perform transbronchial biopsies
• Remove foreign objects

Lung Biopsy: Microscopic Analysis

Lung biopsies, obtained either through bronchoscopy or surgical techniques, allow for microscopic examination of lung tissue. This can be crucial in:

• Diagnosing interstitial lung diseases
• Identifying infections
• Ruling out malignancy

Thoracentesis: Pleural Fluid Analysis

Thoracentesis involves removing fluid from the pleural space, the area between the lungs and the chest wall. Analyzing the fluid can help determine:

• The cause of pleural effusions
• Differentiate between transudative and exudative effusions
• Identify infections or malignancies

Functional and Laboratory Tests: Quantifying Lung Function

Pulmonary Function Tests (PFTs): Assessing Lung Volumes and Airflow

Pulmonary Function Tests (PFTs) measure lung volumes, airflow rates, and gas exchange efficiency. These tests are valuable for:

• Assessing the severity of lung disease
• Monitoring disease progression
• Evaluating the response to treatment

Arterial Blood Gas (ABG): Measuring Blood Oxygen and Carbon Dioxide Levels

Arterial Blood Gas (ABG) analysis measures the levels of oxygen and carbon dioxide in arterial blood. This test provides critical information about:

• A patient's oxygenation status
• Acid-base balance
• The severity of respiratory impairment

Sputum Culture: Identifying Respiratory Infections

Sputum cultures are used to identify bacteria, viruses, or fungi in the sputum, the mucus that is coughed up from the lungs. This test is essential for:

• Diagnosing respiratory infections
• Guiding antibiotic or antifungal therapy

By carefully integrating these diagnostic tools and tailoring their use to individual patient needs, clinicians can effectively identify and manage airspace disease.

Recognizing the Signs: Clinical Presentation

After identifying the potential causes, a crucial step in managing airspace disease is accurate identification. A range of diagnostic modalities are available, each playing a vital role in pinpointing the underlying pathology. From initial clinical assessments to advanced imaging and invasive procedures, clinicians employ a multifaceted approach to determine the nature and extent of the condition. However, before diving into these complex procedures, a keen understanding of the disease's clinical presentation is paramount.

The clinical presentation of airspace disease is highly variable, depending on the underlying etiology, the extent of lung involvement, and the patient's overall health status. While some individuals may exhibit subtle symptoms, others can present with acute respiratory distress requiring immediate intervention.

Common Symptoms: The Patient's Perspective

Patients with airspace disease frequently report a constellation of symptoms that impact their respiratory function and overall well-being. Cough, often productive, is a cardinal symptom, reflecting the inflammatory or infectious processes within the lung parenchyma.

The characteristics of the sputum (color, consistency, presence of blood) can provide valuable clues to the underlying cause.

Shortness of breath (dyspnea) is another prevalent complaint, stemming from the impaired gas exchange capacity of the affected alveoli. The severity of dyspnea can range from exertional breathlessness to profound air hunger at rest.

Chest pain, although less common, can occur, particularly in cases of pleuritic involvement or underlying inflammatory processes. The pain is typically sharp and localized, often exacerbated by breathing or coughing.

Fever, chills, and systemic symptoms may accompany airspace disease, especially when an infectious etiology is involved.

Physical Examination Findings: Clues from Observation

A thorough physical examination can reveal important clues to the presence and severity of airspace disease. Auscultation of the lungs often reveals abnormal breath sounds, such as:

• Crackles (rales), indicating fluid accumulation in the alveoli.
• Wheezes, suggesting airway narrowing or obstruction.
• Diminished breath sounds, reflecting decreased air entry into the affected lung regions.

Percussion of the chest may reveal areas of dullness, indicating consolidation or pleural effusion.

In severe cases, patients may exhibit signs of respiratory distress, including:

• Tachypnea (rapid breathing).
• Use of accessory respiratory muscles.
• Cyanosis (bluish discoloration of the skin and mucous membranes).
• Altered mental status.

Auscultation: Listening to the Lungs

Auscultation remains a cornerstone of the physical examination, providing valuable information about the condition of the lungs and airways. Familiarity with normal and abnormal breath sounds is essential for accurate interpretation.

Crackles, also known as rales, are discontinuous, popping sounds that typically indicate fluid accumulation in the small airways and alveoli. They are often described as sounding like rubbing strands of hair together near the ear.

Wheezes, on the other hand, are continuous, high-pitched whistling sounds that suggest airway narrowing or obstruction. They are commonly heard in patients with asthma, bronchitis, or other obstructive lung diseases.

Absent or diminished breath sounds may indicate complete obstruction of an airway, consolidation of the lung tissue, or pleural effusion.

Recognizing Respiratory Distress: A Critical Assessment

Recognizing the signs of respiratory distress is crucial for timely intervention and prevention of adverse outcomes. Tachypnea, the use of accessory respiratory muscles, cyanosis, and altered mental status are all indicative of severe respiratory compromise.

Prompt assessment of oxygen saturation and arterial blood gases is warranted in these cases.

Early recognition and appropriate management of respiratory distress can significantly improve patient outcomes.

Treatment Strategies: Managing Airspace Disease

Recognizing the Signs: Clinical Presentation After identifying the potential causes, a crucial step in managing airspace disease is accurate identification. A range of diagnostic modalities are available, each playing a vital role in pinpointing the underlying pathology. From initial clinical assessments to advanced imaging and invasive procedures, a comprehensive approach is required to discern the specific etiology and guide appropriate interventions. Following accurate diagnosis, the approach to treatment for airspace disease requires a multifaceted approach, incorporating medical management, supportive care, and the expertise of various medical professionals.

Medical Management: A Pharmacological Arsenal

The cornerstone of airspace disease treatment frequently involves pharmacological interventions tailored to the underlying cause. Appropriate and prompt medical management is paramount in addressing the inflammation, infection, or fluid overload characterizing many airspace diseases.

Targeted Antimicrobial Therapy

In cases of infectious pneumonia, whether bacterial, viral, or fungal, targeted antimicrobial therapy is essential. Antibiotics are chosen based on the likely pathogen, considering factors like community-acquired versus hospital-acquired infection and local resistance patterns. Antiviral medications are deployed for viral pneumonias like influenza, and antifungals are used to combat fungal infections such as Pneumocystis pneumonia.

Diuretics for Fluid Overload

Pulmonary edema, whether cardiogenic or non-cardiogenic, often necessitates the use of diuretics. These medications help to reduce fluid accumulation in the alveoli, improving gas exchange and alleviating respiratory distress.

Corticosteroids for Inflammation

Inflammatory conditions such as aspiration pneumonitis or acute respiratory distress syndrome (ARDS) may require corticosteroids to suppress the inflammatory response. However, the use of corticosteroids must be carefully weighed against the potential side effects, particularly in the context of infection.

Supportive Care: Optimizing Respiratory Function

In addition to medical management, supportive care plays a critical role in stabilizing patients with airspace disease and promoting recovery.

Oxygen Therapy

Supplemental oxygen is frequently required to maintain adequate oxygen saturation. The mode of oxygen delivery ranges from nasal cannulas and face masks to high-flow nasal cannula (HFNC) systems, depending on the severity of hypoxemia.

Mechanical Ventilation

In severe cases of ARDS or respiratory failure, mechanical ventilation becomes necessary. Mechanical ventilation strategies, including lung-protective ventilation, aim to minimize ventilator-induced lung injury while ensuring adequate oxygenation and carbon dioxide removal. The decision to intubate and mechanically ventilate is a complex one that requires careful consideration of the patient's clinical status and prognosis.

The Multidisciplinary Team: Collaborative Expertise

Effective management of airspace disease requires a collaborative approach involving a diverse team of medical professionals.

The Pulmonologist's Central Role

Pulmonologists are central to the diagnostic and therapeutic management of airspace disease. They lead the evaluation, diagnosis, and treatment of patients with complex respiratory conditions.

Radiology's Diagnostic Insight

Radiologists provide critical insights through the interpretation of chest X-rays and CT scans, helping to identify the extent and nature of airspace abnormalities.

Respiratory Therapists' Essential Support

Respiratory therapists administer oxygen therapy, manage mechanical ventilation, and provide airway clearance techniques. Their expertise is essential in optimizing respiratory function and preventing complications.

Pathology's Detailed Analysis

Pathologists analyze lung biopsy specimens and bronchoalveolar lavage fluid to identify the underlying cause of airspace disease, particularly in cases where the diagnosis is uncertain.

Critical Care Physicians' Intensive Management

Critical care physicians/intensivists manage patients with severe respiratory failure in the intensive care unit, coordinating the efforts of the multidisciplinary team and implementing advanced life support measures.

The Importance of Interdisciplinary Collaboration

The complexities of airspace disease demand seamless interdisciplinary collaboration. Regular communication and shared decision-making are essential to ensure optimal patient outcomes.

This collaborative approach ensures that all aspects of the patient's condition are addressed, from diagnosis and treatment to supportive care and rehabilitation. By leveraging the expertise of each team member, clinicians can provide comprehensive and coordinated care that maximizes the chances of recovery and improves the patient's quality of life.

Specific Conditions: Focused Insights

Treatment strategies for airspace disease vary greatly depending on the underlying cause. Therefore, a deeper dive into specific conditions is essential for informed clinical decision-making. This section will focus on several common causes of airspace disease, providing focused insights into their unique characteristics and management approaches.

Pneumonia

Pneumonia, an inflammatory condition of the lungs, is a leading cause of airspace disease. Distinguishing between community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) is critical, as the causative organisms and antibiotic resistance patterns differ significantly.

Community-Acquired Pneumonia (CAP)

CAP often results from common bacteria like Streptococcus pneumoniae or atypical pathogens like Mycoplasma pneumoniae. Management typically involves empirical antibiotic therapy tailored to local resistance patterns.

Hospital-Acquired Pneumonia (HAP)

HAP, on the other hand, is frequently caused by more resistant organisms such as Pseudomonas aeruginosa or Staphylococcus aureus. In these cases, broader-spectrum antibiotics and careful assessment of antibiotic sensitivities are imperative. Severity scoring systems like CURB-65 aid in risk stratification and guide appropriate treatment settings (outpatient vs. inpatient).

Pulmonary Edema

Pulmonary edema refers to the accumulation of fluid in the lungs, specifically in the alveoli and interstitial spaces. It’s critical to differentiate between cardiogenic and non-cardiogenic causes.

Cardiogenic Pulmonary Edema

Cardiogenic pulmonary edema results from elevated pulmonary capillary wedge pressure due to heart failure. Treatment focuses on reducing preload and afterload with diuretics, vasodilators, and inotropic agents. Addressing the underlying cardiac dysfunction is paramount.

Non-Cardiogenic Pulmonary Edema

Non-cardiogenic pulmonary edema, as seen in acute respiratory distress syndrome (ARDS), is caused by increased pulmonary vascular permeability. Management focuses on supportive care, addressing the underlying cause, and preventing further lung injury.

Acute Respiratory Distress Syndrome (ARDS)

ARDS represents a severe form of acute lung injury characterized by widespread inflammation and increased permeability of the alveolar-capillary barrier. Recognizing risk factors, such as sepsis, pneumonia, and trauma, is essential for early intervention.

Lung-Protective Ventilation

Implementing lung-protective ventilation strategies, including low tidal volumes and limiting plateau pressures, is crucial to minimize ventilator-induced lung injury. Prone positioning and neuromuscular blockade may be considered in severe cases.

Aspiration Pneumonitis

Aspiration pneumonitis occurs when gastric contents are inhaled into the lungs, leading to chemical pneumonitis and potential secondary bacterial infection.

Prevention and Management

Prevention strategies, such as elevating the head of the bed and optimizing swallowing function, are vital in at-risk patients. Management includes supportive care, bronchoscopy for removal of particulate matter, and antibiotics if secondary infection develops. Corticosteroids may be considered in specific cases to reduce inflammation.

Other Interstitial Lung Diseases (ILDs)

ILDs comprise a heterogeneous group of disorders characterized by inflammation and fibrosis of the lung parenchyma.

Specific ILD Examples

Sarcoidosis, characterized by non-caseating granulomas, often requires corticosteroids or immunosuppressants. Cryptogenic Organizing Pneumonia (COP) typically responds well to corticosteroids. Hypersensitivity pneumonitis, triggered by inhaled antigens, necessitates avoidance of the offending agent and may require corticosteroids in some cases. A multidisciplinary approach involving pulmonologists, radiologists, and pathologists is crucial for accurate diagnosis and tailored therapeutic strategies.

Monitoring Progress: Follow-Up Care

Treatment strategies for airspace disease vary greatly depending on the underlying cause. Therefore, a deeper dive into specific conditions is essential for informed clinical decision-making. This section will focus on several common causes of airspace disease, providing focused insights into their unique characteristics and management strategies.

The Imperative of Regular Assessment

Effective management of airspace disease hinges not only on accurate initial diagnosis and appropriate treatment, but also on diligent monitoring and adaptation of the therapeutic approach. The respiratory system is dynamic, and patient responses to interventions can vary widely. Therefore, a static treatment plan is rarely sufficient. Regular assessment allows clinicians to identify subtle changes in a patient's condition, detect potential complications early, and tailor the treatment regimen to optimize outcomes.

Methods for Monitoring Respiratory Status

Several methods are employed to monitor respiratory status in patients with airspace disease. These methods provide complementary information, enabling a comprehensive understanding of the patient's progress and response to treatment.

Clinical Evaluation

A thorough clinical evaluation remains a cornerstone of patient monitoring. This includes assessing the patient's subjective experience, such as the severity of dyspnea, cough frequency and characteristics, and overall sense of well-being.

Physical examination findings, such as respiratory rate, auscultation of lung sounds, and signs of respiratory distress (e.g., use of accessory muscles, cyanosis), provide valuable objective data. Serial clinical evaluations can reveal trends that indicate improvement, stabilization, or deterioration.

Arterial Blood Gas (ABG) Analysis

ABG analysis is an invaluable tool for assessing gas exchange efficiency. It provides objective measurements of arterial oxygen tension (PaO2), arterial carbon dioxide tension (PaCO2), and pH, allowing clinicians to determine the presence and severity of hypoxemia, hypercapnia, and acid-base imbalances.

Serial ABG measurements can track changes in these parameters over time, reflecting the impact of treatment on respiratory function. ABG results should always be interpreted in the context of the patient's clinical presentation.

Repeat Imaging

Radiological imaging plays a crucial role in monitoring the resolution of airspace disease. Chest X-rays are often used for initial assessment and follow-up, but Computed Tomography (CT) scans may be necessary to provide more detailed information.

Serial imaging can document the clearing of infiltrates, the reduction in pulmonary edema, or the progression of fibrosis. It is important to consider the potential risks associated with radiation exposure, particularly with repeated CT scans. The frequency of imaging should be carefully weighed against the clinical benefits.

Tailoring Treatment to Patient Response

The ultimate goal of monitoring is to inform treatment decisions and ensure that the patient receives the most appropriate and effective care. Treatment plans should not be rigid protocols, but rather dynamic strategies that are adjusted based on the patient's individual response.

If a patient is responding well to treatment, the intensity of therapy may be gradually reduced. Conversely, if a patient is not improving or is deteriorating, the treatment plan may need to be escalated, which may involve:

• Adjusting medication dosages.
• Adding new medications.
• Increasing the level of respiratory support.

Close monitoring and individualized treatment strategies are essential for optimizing outcomes in patients with airspace disease.

Video: Airspace Disease: Symptoms, Diagnosis & Treatment

Play Video

So, that's the lowdown on airspace disease. It can sound scary, but with the right diagnosis and treatment plan, you can definitely manage it. If you're experiencing any of the symptoms we talked about, don't hesitate to chat with your doctor. Catching airspace disease early makes a real difference!